Fischer Medical Ventures operates in Healthcare Equipment & Supplies (₹2,529 Cr market cap). Consolidated and standalone entities with significant operational volatility; quarterly revenues ₹23–101 Cr, latest results show profitability pressure.
Generated analysis · source review pending
Generated analysis · source review pending
556 historical price candles were omitted because the exchange source has not been verified.
Structured signal from quality, growth, valuation and momentum.
₹ crore, by fiscal year
% of revenue, by fiscal year
Comparable companies from the narrowest available industry classification.
Reported profit and loss, balance sheet, cash flow and growth history.
Annual operating, return, leverage and working-capital ratios.
Current futures and options contracts with compact option-chain pages.
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
Mutual-fund schemes that disclosed a holding in the company.
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Upcoming dates and the company’s corporate-action history.
Latest exchange announcements, filings and downloadable documents.
| Holder (%) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0% | 0% | 0% | 74.91% | 74.91% | 74.91% | 62.81% | 61.8% | 61.8% | 61.8% | 62.15% | 62.15% | |
| 0% | 0% | 5.07% | 5.07% | 5.07% | 5.07% | 5.23% | 5.55% | 5.57% | 4.85% | 4.97% | 5.48% | |
| 0% | 0% | 1.68% | 1.68% | 1.68% | 1.68% | 1.44% | 1.42% | 1.42% | 1.36% | 1.38% | 1.35% | |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 100% | 100% | 93.25% | 18.34% | 18.34% | 18.34% | 30.52% | 31.23% | 31.21% | 31.99% | 31.5% | 31.02% | |
| No. of shareholders | — | — | — | — | — | — | — | — | 13,054 | 22,920 | 23,269 | 23,950 |
Promoter holding up 62.15 percentage points since Sep 2023.
| Date | Client | Type | Venue | Side | Quantity | Price | Value |
|---|---|---|---|---|---|---|---|
| 22 Sept 2026 | TRADE SOLVENT PRIVATE LIMITED | Bulk | NSE | Buy | 64,36,907 | ₹32.95 | ₹21.21 Cr |
| 22 Sept 2026 | L7 HITECH PRIVATE LIMITED | Bulk | NSE | Sell | 64,36,907 | ₹32.95 | ₹21.21 Cr |
| 22 Sept 2026 | L7 HITECH PRIVATE LIMITED | Bulk | NSE | Buy | 3,05,000 | ₹32.98 | ₹1.01 Cr |
| 10 Apr 2023 | ANAND MOHAN | Bulk | BSE | Sell | 1,258 | ₹79.80 | ₹0.01 Cr |
| 30 Jun 2022 | KETAN RASHIKLAL DOSHI | Bulk | BSE | Buy | 900 | ₹66.60 | ₹0.01 Cr |
| 17 Jun 2022 | KIRTAN JITENDRA BHAI PATEL | Bulk | BSE | Buy | 996 | ₹79.97 | ₹0.01 Cr |
| 27 Dec 2021 | MOHAMMADZAHIDHUSSAIN | Bulk | BSE | Buy | 1,000 | ₹93.20 | ₹0.01 Cr |
| 27 Dec 2021 | RAVINDRADADAJIJILTE | Bulk | BSE | Sell | 973 | ₹93.27 | ₹0.01 Cr |
| 23 Aug 2021 | ARUNKUMAR | Bulk | BSE | Buy | 932 | ₹90.07 | ₹0.01 Cr |
Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.
Current officeholders as filed with BSE. A person holding two offices is listed once per office.
| Company | Mkt Cap | EV | Revenue | EBITDA | OPM | PAT | NPM | ROCE | ROE | WC Days |
|---|---|---|---|---|---|---|---|---|---|---|
| Molbio Diagnostics LimitedMOLBIOMOLBIO | ₹17,431 Cr | ₹17,844 Cr | ₹1,020 Cr | ₹262 Cr | 25.7% | ₹145 Cr | 13.6% | 23.7% | 16.2% | — |
| Poly Medicure LimitedPOLYMEDPOLYMED | ₹16,610 Cr | ₹16,952 Cr | ₹1,997 Cr | ₹461 Cr | 23.6% | ₹315 Cr | 17.1% | 14.5% | 11% | 294 |
| Fischer Medical Ventures LimitedFISCHERFISCHER | ₹2,190 Cr | ₹2,262 Cr | ₹367 Cr | ₹50 Cr | 14% | ₹30 Cr | 10.1% | 13.6% | 8.6% | 111 |
| Tarsons Products LimitedTARSONSTARSONS | ₹1,752 Cr | ₹2,135 Cr | ₹441 Cr | ₹119 Cr | 27.9% | ₹11 Cr | 3.4% | 5% | 2.3% | 361 |
| Laxmi Dental LimitedLAXMIDENTLLAXMIDENTL | ₹1,066 Cr | ₹1,066 Cr | ₹287 Cr | ₹46 Cr | 15.6% | ₹31 Cr | 10.4% | 14.7% | 12.8% | 109 |
| Hemant Surgical Industries LtdHSILHSIL | ₹885 Cr | — | ₹232 Cr | ₹23 Cr | 10% | ₹18 Cr | 7.9% | — | — | — |
| Fabtech Technologies LimitedFABTECHFABTECH | ₹632 Cr | ₹675 Cr | ₹418 Cr | ₹45 Cr | 8.5% | ₹49 Cr | 9.3% | 15.5% | 12.9% | 55 |
| Prevest Denpro LtdPREVESTPREVEST | ₹452 Cr | — | ₹72 Cr | ₹25 Cr | 34.4% | ₹20 Cr | 28.5% | — | — | — |
| Nureca LimitedNURECANURECA | ₹332 Cr | ₹333 Cr | ₹153 Cr | ₹4 Cr | 0.1% | ₹4 Cr | 1.4% | 3.3% | 1.1% | 186 |
| Earkart LtdEARKARTEARKART | ₹179 Cr | ₹179 Cr | ₹54 Cr | ₹8 Cr | 15.5% | ₹5 Cr | 9.1% | 12.1% | 7.7% | 243 |
| Choksi Asia LtdCHOKSICHOKSI | ₹117 Cr | ₹119 Cr | ₹11 Cr | ₹-2 Cr | 13.8% | ₹2 Cr | 10.8% | 18.9% | 13.5% | 142 |
| Shree Pacetronix LtdSHREEPACSHREEPAC | ₹68 Cr | ₹71 Cr | ₹8 Cr | ₹1 Cr | 23.5% | ₹0 Cr | 14% | 27.4% | 18.9% | 385 |
Consolidated figures
| Ratio | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Margins | |||||||
| Gross margin % | — | — | — | — | 21.5% | 17.3% | 53.8% |
| EBITDA margin % | -11.1% | -11.8% | — | 11.1% | 8.9% | 3% | 14% |
| EBIT margin % | -11.1% | -11.8% | — | 11.1% | 8% | 1.5% | 13% |
| PAT margin % | -22.2% | 82.4% | — | -22.2% | 8.8% | 1.1% | 10.1% |
| Working capital | |||||||
| Receivable days | — | — | — | — | 398 | 251 | 342 |
| Inventory days | — | — | — | — | 99 | 37 | 32 |
| Payable days | — | — | — | — | 48 | 82 | 263 |
| NWC days | — | — | — | — | 449 | 205 | 111 |
| Leverage | |||||||
| Current ratio | 2.33 | 4 | 0.12 | 0.4 | 18.38 | 3.59 | 1.62 |
| Debt to EBITDA | — | — | — | 28.5 | 0 | 18.08 | 1.68 |
| Debt to equity | -1.57 | — | -1.7 | -2.11 | 0 | 0.18 | 0.19 |
| Interest coverage | -1 | -1 | -19 | 1 | 31.1 | 6.5 | 9 |
| Asset turnover | 1.29 | 0.68 | 0 | 0.51 | 0.24 | 0.24 | 0.46 |
| Return ratios | |||||||
| Return on assets % | -28.6% | 56% | -121.1% | -11.4% | 2.1% | 0.3% | 4.6% |
| Return on capital employed % | -25% | -12.9% | -13,69,09,42,86,72,06,30,800% | -7.4% | 2.6% | 1.5% | 13.6% |
| Return on equity % | 28.6% | — | 100% | 14.8% | 2.3% | 0.4% | 8.1% |
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
Documents link to external sources (exchange filings, company investor pages).
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Shareholder Meeting / Postal Ballot-Outcome of AGM
General Update
Presentation Of Investor/Analyst Meeting
Chairman''s Message
Announcement under Regulation 30 (LODR)-Newspaper Publication
Business Responsibility and Sustainability Reporting (BRSR)
Reg. 34 (1) Annual Report.
| 28 Sept 2026, 6:30 pm | Company Update General | General Update |
| 17 Sept 2026, 4:01 pm | Company Update General | Presentation Of Investor/Analyst Meeting |
| 16 Sept 2026, 3:47 pm | Company Update General | Chairman''s Message |
| 9 Sept 2026, 11:41 am | Company Update Newspaper Publication | Announcement under Regulation 30 (LODR)-Newspaper Publication |
| 7 Sept 2026, 9:10 pm | Others Business Responsibility and Sustainability Reporting (BRSR) | Business Responsibility and Sustainability Reporting (BRSR) |
| 7 Sept 2026, 8:42 pm | Others Reg. 34 (1) Annual Report | Reg. 34 (1) Annual Report. |
2 schemes
| Shares | ||||||
|---|---|---|---|---|---|---|
| (Investment Manager for Motilal Oswal Mutual Fund) | Motilal Oswal Mutual Fund | 6,760 | 0.02 | 0.05% | 0.001% | +10 |
| (Investment Manager for Motilal Oswal Mutual Fund) | Motilal Oswal Mutual Fund | 731 | 0 | 0% | 0% | +1 |
Consolidated figures · ₹ crore
| ₹ Cr | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 21 | 111 | 309 | |
| COGS | — | — | — | — | 16 | 92 | 143 |
| Gross profit | — | — | — | — | 5 | 19 | 166 |
| — | — | — | — | 3 | 16 | 123 | |
| -0 | -0 | -0 | 0 | 2 | 3 | 43 | |
| OPM % | -11.1% | -11.8% | — | 11.1% | 8.9% | 3% | 13.9% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| 0 | 0 | 0 | 0 | 1 | 1 | 12 | |
| Profit before tax | -0 | -0 | -0 | 0 | 2 | 2 | 46 |
| Tax | — | — | — | — | 0 | 1 | 15 |
| Tax % | — | — | — | — | 12.8% | 45.5% | 33.1% |
| -0 | 0 | -0 | -0 | 2 | 1 | 31 | |
| PAT margin % | -22.2% | 82.4% | — | -22.2% | 8.8% | 1.1% | 10.1% |
| EPS (₹) | — | — | — | — | 1.7 | 0.1 | 0.5 |
| EPS adjusted (₹) | -0.2 | 0.8 | -1.4 | -0.2 | 0 | 0 | 0.5 |
| — | — | — | — | 0% | 6.3% | 10.4% | |
| Annual report | Annual report for Mar 2020 | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | — |
| ₹ Cr | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 54 | 64 | 65 |
| Reserves | -0 | -0 | -0 | -0 | 28 | 274 | 319 |
| Minority interest | — | — | — | — | — | 0 | 1 |
| 0 | 0 | 0 | 1 | 0 | 60 | 72 | |
| 0 | 0 | 0 | 0 | 5 | 59 | 214 | |
| Total equity & liabilities | 0 | 0 | 0 | 0 | 86 | 457 | 671 |
| 0 | 0 | 0 | 0 | 15 | 24 | 18 | |
| CWIP | — | — | — | — | 0 | 1 | 3 |
| Investments | — | — | — | — | 1 | 11 | 118 |
| — | — | — | — | 70 | 422 | 533 | |
| Total assets | 0 | 0 | 0 | 0 | 86 | 457 | 671 |
| ₹ Cr | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| 0 | -0 | -0 | 0 | -7 | -87 | -101 | |
| 0 | — | — | — | -31 | -125 | -5 | |
| 0 | 0 | 0 | -0 | 40 | 315 | 14 | |
| Net cash flow | 0 | — | — | — | 1 | 103 | -92 |
| Free cash flow | — | — | — | — | -8 | -93 | -103 |
| CFO / Operating profit % | — | — | — | 150% | -395.2% | — | -235.1% |